DALLAS and FORT WORTH, Texas, May 05, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc.
(Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the
treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that it will report financial results for the first
quarter of 2016 on Monday, May 16, 2016, before the market opens. Management will host a conference call beginning at 8:30 a.m.
Eastern Time that day to review results and provide a company update.
To access the call, dial 877-388-8985 (U.S.) or 562-912-2654 (outside of the U.S.). The Conference ID is
94145468. A live webcast will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/. Please log in approximately 5-10 minutes prior to the scheduled
start time.
The archived webcast will be available on the company’s Investor Relations page under Presentations.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its
proprietary modified‐release drug delivery technology platforms. The Company recently received FDA approval of Adzenys XR-ODT™ -
the first and only FDA-approved amphetamine extended-release orally disintegrating tablet for the treatment of ADHD. Neos has two
other branded product candidates in development, an XR-ODT of methylphenidate and a liquid suspension of amphetamine for the
treatment of ADHD. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®1,
an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a
cold.
1Tussionex® is a registered trademark of the UCB Group of Companies
CONTACTS: Richard I. Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408‐1389 reisenstadt@neostx.com David Carey, Investor Relations Lazar Partners (212) 867‐1768 dcarey@lazarpartners.com
